The Impact of Reactive Oxygen Species and Matrix Metalloproteinases on Cardiometabolic Diseases

Matrix metalloproteinases (MMPs) and reactive oxygen species (ROS) are known to play significant roles in the development and progression of various cardiometabolic diseases. Cardiometabolic diseases represent a cluster of health disorders that concurrently impact the cardiovascular system and metabolism. These conditions collectively heighten the risk of developing cardiovascular diseases and Type-2 diabetes. These diseases are influenced by the diverse functions of MMPs and ROS. MMPs are a family of enzymes that, although primarily recognized for their ability to degrade extracellular matrix components, also possess intracellular and nuclear functions. These novel roles contribute to the complex mechanisms underlying various pathologies, including cardiometabolic diseases. On the other hand, ROS are molecules that can activate MMPs through different pathways: directly by modifying the cysteine residues within the MMPs or indirectly by increasing the gene expression of MMPs. Therefore, targeting MMPs has emerged as a promising therapeutic strategy for treating cardiometabolic diseases. However, further research is needed to identify the most suitable MMP targets and to develop effective inhibition techniques. To fully realize the potential of MMP-based therapies, we must consider aspects such as substrate specificity, extracellular vs. intracellular targets of the enzymes, and the selectivity of the inhibitors. Large-scale clinical trials, particularly phase III trials, are still lacking but crucial for validating the clinical benefits and safety of MMP inhibitors. By understanding the context-dependent roles of MMPs and the various factors that influence their activity, we can develop improved therapeutic strategies for managing and treating cardiometabolic diseases. In the future, this knowledge may lead to the development of more targeted and effective therapies for these pathological conditions.